A5026664071- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Cytokine Signaling Pathways and Interactions
- Mechanisms of cancer metastasis
- Breast Cancer Treatment Studies
- Metabolism, Diabetes, and Cancer
- Prostate Cancer Treatment and Research
- Melanoma and MAPK Pathways
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
- Histone Deacetylase Inhibitors Research
- HER2/EGFR in Cancer Research
- Ubiquitin and proteasome pathways
- PARP inhibition in cancer therapy
- 3D Printing in Biomedical Research
- Nuclear Structure and Function
- Ferrocene Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- Cancer, Hypoxia, and Metabolism
- Protein Degradation and Inhibitors
- Cancer-related molecular mechanisms research
- 14-3-3 protein interactions
- Multiple Myeloma Research and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Epigenetics and DNA Methylation
Royal College of Surgeons in Ireland
2017-2024
University of Medicine and Health Sciences
2024
Discovery of a new HDAC6 inhibitor reveals role for in the regulation glycolytic metabolism.
Divergent roles for androgen receptor (AR) in breast cancer have been reported. Following aromatase inhibitor (AI) treatment, the conversion of circulating androgens into estrogens can be diminished by >99%. We wished to establish whether steroid environment dictate role AR and implications this subsequent therapy. This study utilizes models AI resistance explore responsiveness PI3K/mTOR anti-AR therapy when cells are exposed unconverted weak androgens. Transcriptomic alterations driven...
Abstract Purpose: There is strong epidemiologic evidence indicating that estrogens may not be the sole steroid drivers of breast cancer. We hypothesize abundant adrenal androgenic precursors, acting via androgen receptor (AR), promote an endocrine-resistant cancer phenotype. Experimental Design: AR was evaluated in a primary tissue microarray (n = 844). Androstenedione (4AD) levels were serum samples 42) from hormone receptor–positive, postmenopausal Levels androgens, progesterone, and...
Abstract Background: Invasive lobular carcinoma (ILC) is the second most pervasive subtype after invasive ductal (IDC), accounting for approximately 10-15% of all breast cancers. It characterized by loss E-cadherin expression and non-adherent tumor cells that invade stroma in a “single-file” pattern. Women with ILC are typically diagnosed at an older age later stage ER-positive disease. more likely to exhibit late recurrence metastasize gastrointestinal tract urogenital compared IDC....
<p>KM survival data based on therapy</p>
<div>AbstractPurpose:<p>There is strong epidemiologic evidence indicating that estrogens may not be the sole steroid drivers of breast cancer. We hypothesize abundant adrenal androgenic precursors, acting via androgen receptor (AR), promote an endocrine-resistant cancer phenotype.</p>Experimental Design:<p>AR was evaluated in a primary tissue microarray (<i>n</i> = 844). Androstenedione (4AD) levels were serum samples 42) from hormone receptor–positive,...
<p>TMA images showing AR expression level by IHC in samples used trasnscriptomic analysis</p>
<p>Supplementary Methods</p>
<p>Androstenedione driven gene changes post AI therapy (+ months)</p>
<p>Steroid profiles of breast cancer patient serum (recurrent versus non-recurrent).</p>
Abstract Purpose Aromatase Inhibitors (AI) are standard therapy for hormone receptor positive breast cancers in post-menopausal patients. Disease recurrence is common and previous studies suggest that the altered steroid environment may be a driver of resistance. Using label-free mass-spectrometry we explored unique androgen (AR) interactome supervenes AI resistant cancer associated hyperandrogenic environment. Experimental Design AR expression was evaluated primary tissue-microarray (n=875)...
Introduction AI’s are the front line treatment for endocrine postmenopausal breast cancer. However, response rates vary from 35%–70% and recurrence occurs in almost all advanced disease. In order to identify a target overcoming AI resistance, research has turned most widely expressed sex steroid receptor cancer AR. therapies, by their mechanism of action, create an unopposed androgenic environment. 4AD is major circulating women and therapy prevents it’s conversion estrogens. We hypothesise...
<p>Supplemental tables 1& 2</p>
<p>Impact of SiSGK3 in ZRaroLetR. MTS following siSGK3 under various hormonal stimuli.</p>
<p>Characterisation of ZR75aro-LetR. Validation ER AR siRNA</p>
<p>AR and ER binding events in the proximal promoters of SGK3, MYBL1, GREB1 PKIB.</p>
<p>Correlation between CYP19 amplification and SGK3 expression.</p>
<p>Supplemental methods</p>